Other targets for BiT therapy that are expressed in different PCa subtypes are being studied, including delta-like protein 3 (DLL3), human carcinoembryonic antigen (CEA)-related cell adhesion molecule 5, and six-transmembrane prostate epithelial antigen (STEAP) [155,156]. The gene discussed is CEACAM5; the disease is posterior cortical atrophy.